Ac immune reports top line results from tauriel phase 2 trial evaluating semorinemab in early alzheimer’s disease

Ac immune reports top line results from tauriel phase 2 trial evaluating semorinemab in early alzheimer’s disease.ac immune sa - genentech disclosed anti-tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the tauriel study.ac immune sa - investigational new drug (ind) enabling studies ongoing for first-in-class therapeutic candidates targeting tdp-43 and alpha-synuclein.ac immune sa - genentech, informed co of study results which show that semorinemab did not meet its primary efficacy endpoint.ac immune sa - ac immune remains in a strong financial position with operations fully financed through q1 2024.
ACIU Ratings Summary
ACIU Quant Ranking